Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Withdrawn 2Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neutropenia 1Neoplasms 1Mycoses 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × posaconazole × Clear all
NCT00686543 2017-04-07

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

Merck Sharp & Dohme LLC

Phase 4 Completed
75 enrolled 14 charts
Other hematologic neoplasm

Mycoses, Neutropenia, Leukemia, Myeloid, Acute

NCT01901172 2015-08-18

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
61 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡